JANE DE LARTIGUE, PH.D.

A leader of the Pancreatic Cancer Action Network, which aims to double survival rates by 2020, outlines treatment strategies that could lead to success.

In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.

Josh D. Lauring, of Johns Hopkins Medicine, is interested in identifying the genetic changes that drive breast cancer growth in order to determine novel therapeutic targets for drug development and ultimately improve outcomes for patients with breast cancer.